The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience - 10/06/22
Highlights |
• | Low percentage of NAFLD patients are metabolically healthy. |
• | Metabolically healthy NAFLD patients present a more propitious biochemical profile compared to metabolically unhealthy people. |
• | Metabolically non-healthy NAFLD patients do not present a significantly higher risk of liver disease compared to metabolically healthy patients. |
Abstract |
Background |
The role of patients’ metabolic clinical and biochemical profile in NAFLD has not been extensively explored.
Aims |
The aim of the study was to assess the role of metabolic health in NAFLD patients and to examine liver disease progression in these populations.
Methods |
The medical charts of 569 patients diagnosed with fatty liver were thoroughly reviewed; 344 patients were excluded because of other chronic liver diseases. Metabolically healthy people were defined as those who met none of the following criteria: blood pressure ≥ 130/85 mmHg or under hypertension treatment, fasting glucose ≥ 100 mg/dl or under diabetes treatment, serum triglycerides > 150 mg/dl, high density lipoprotein-cholesterol <40/50 mg/dl for men/women. Study participants were followed-up over a median period of 22 months.
Results |
The present observational case-control study included 225 NAFLD patients; 14 (6.2%) were metabolically healthy. Metabolically healthy participants were younger (p = 0.006), had lower age at diagnosis (p = 0.002), lower levels of γ-GT (p = 0.013), fasting glucose (p <0.001) and triglycerides (p <0.001) and higher HDL-cholesterol (p = 0.005) compared to metabolically non-healthy. By the last follow up assessment, 8 metabolically healthy patients had developed dyslipidemia; 1 patient (14.4%) had presented liver disease progression compared to 8 patients (10.5%) from the unhealthy group (p = 0.567). In multivariate analysis, diabetes mellitus (p = 0.017) and hemoglobin levels (p = 0.009) were the sole independent predictors of disease progression. No significant difference was observed in liver disease progression-free survival rates among the two patient groups (p = 0.503).
Conclusions |
Metabolically healthy NAFLD patients presented with a favorable biochemical profile; however, they were diagnosed with NAFLD at a younger age and the liver disease progression risk was similar to that of metabolically unhealthy patients. These findings suggest that metabolically healthy NAFLD may not constitute a benign condition and patients could potentially be at increased risk of metabolic syndrome and liver disease progression.
El texto completo de este artículo está disponible en PDF.Keywords : Metabolically healthy patients, Nonalcoholic fatty liver disease (NAFLD), Fatty liver, Metabolic syndrome (MetS), Liver disease
Abbreviations : NAFLD, NASH, T2DM, HCC, HBV, HCV, HIV, BMI, WC, HOMA-IR, SGOT, SGPT, ALP, γ-GT, HDL, LDL, INR, AFP, AASLD, WHO, IQR
Esquema
Vol 46 - N° 5
Artículo 101896- mai 2022 Regresar al número
Artículo precedente
- Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19
- Simona Tripon, Pascal Bilbault, Thibaut Fabacher, Nicolas Lefebvre, Sylvain Lescuyer, Emmanuel Andres, Elise Schmitt, Sabrina Garnier-KepKA, Pierrick Le Borgne, Joris Muller, Hamid Merdji, Frédéric Chaffraix, Didier Mutter, Thomas F Baumert, Ferhat Meziani, Michel Doffoel
- MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer
- Emeric Boisteau, Alexandra Lespagnol, Marie De Tayrac, Sébastien Corre, Anthony Perrot, Nathalie Rioux-Leclercq, Séverine Martin-Lannerée, Pascal Artru, Philippe Chalabreysse, Pierre-Guillaume Poureau, Laurent Doucet, Dahna Coupez, Jaafar Bennouna, Céline Bossard, Romain Coriat, Frédéric Beuvon, Lucile Bauguion, François Leclair, Romain Chautard, Thierry Lecomte, Serge Guyetant, Romain Desgrippes, Denis Grasset, Hélène Lhostis, Karine Bouhier-Leporrier, Frédéric Bibeau, Julien Edeline, Marie-Dominique Galibert, Astrid Lièvre
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?